First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.02199 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Reinhard Dummer und 25 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Brain Neoplasms, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in clinically diverse patient populations with advanced melanoma. METHODS Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg (240 mg following a protocol amendment) once every 2 weeks for ≤24 months. The primary end point was the incidence of grade 3-5 select treatment-related adverse events (TRAEs). Overall survival (OS) was a secondary end point. Outcomes were evaluated in subgroups defined by Eastern Cooperative Oncology Group performance status (ECOG PS), brain metastasis status, and melanoma subtype. RESULTS In total, 533 patients received at least one dose of study drug. Grade 3-5 select TRAEs affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems occurred in the all-treated population; similar incidence rates were observed across all subgroups. At 21.6 months' median follow-up, 24-month OS rates were 63% in the all-treated population, 44% in the ECOG PS 2 subgroup (including patients with cutaneous melanoma only), 71% in the brain metastasis subgroup, 36% in the ocular/uveal melanoma subgroup, and 38% in the mucosal melanoma subgroup. CONCLUSION Nivolumab plus ipilimumab followed by nivolumab monotherapy was tolerable in patients with advanced melanoma and poor prognostic characteristics. Efficacy was similar between the all-treated population and patients with brain metastases. Reduced efficacy was observed in patients with ECOG PS 2, ocular/uveal melanoma, and/or mucosal melanoma, highlighting the continued need for novel treatment options for these difficult-to-treat patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Zurich, Zurich, Switzerland.
- Addenbrooke's Hospital, Cambridge, United Kingdom.
- Medizinische Hochschule Hannover, Hannover, Germany.
- Johannes-Wesling Medical Center, Ruhr University Bochum Campus, Minden, Germany.
- Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Western Australia, Australia.
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ORCID-Profile: Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M Meniawy, Céleste Lebbé, Brigitte Dreno, Pier Francesco Ferrucci, Jean-Jacques Grob, James Larkin, Sandrine Mansard, Massimo Guidoboni, Erika Richtig, Rudolf Herbst, Maurice Lobo, Paolo A Ascierto, Michele Maio
Zitieren
APA
Dummer, R., Corrie, P., Gutzmer, R., Meniawy, T. M., Del Vecchio, M., Lebbé, C., Guida, M., Dutriaux, C., Dreno, B., Meyer, N., Ferrucci, P. F., Dalle, S., Khattak, M. A., Grob, J. J., Briscoe, K., Larkin, J., Mansard, S., Lesimple, T., Guidoboni, M., …, & Maio, M. (2023). First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02199
Vancouver
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, et al. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02199
BibTeX
@article{Dummer2023,
author = {Dummer, Reinhard and Corrie, Pippa and Gutzmer, Ralf and Meniawy, Tarek M and Del Vecchio, Michele and Lebbé, Céleste and Guida, Michele and Dutriaux, Caroline and Dreno, Brigitte and Meyer, Nicolas and Ferrucci, Pier Francesco and Dalle, Stéphane and Khattak, Muhammad Adnan and Grob, Jean-Jacques and Briscoe, Karen and Larkin, James and Mansard, Sandrine and Lesimple, Thierry and Guidoboni, Massimo and Sabatini, Silvia and Richtig, Erika and Herbst, Rudolf and Lobo, Maurice and Askelson, Margarita and Ascierto, Paolo A and Maio, Michele},
title = {First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.02199}
}
EUVIMED